asthma phenotypes, eval

Introduction to Asthma Epidemic and Therapies

In 1990, the speaker, a baby fellow at the time, noted that asthma was becoming an epidemic. Despite a lack of understanding of the situation, patient numbers continued to rise significantly. This ongoing increase highlighted a critical need for advancements in treatment options.

Current Asthma Therapies

Pathophysiology Understanding

Over time, understanding of the pathophysiology of asthma has greatly improved. Initially, anti-inflammatory therapy was underappreciated; however, it is now recognized as the cornerstone of asthma management. Current therapeutic approaches include:

  1. Dual Therapy: Combining at least two different types of medications.

  2. Triple Therapy: Using three different medications to target various aspects of asthma treatment.

  3. Precision Biologics: Recent advances in biologic therapies cater to specific subtypes of asthma, offering hope for future treatments.

Uncontrolled Asthma

Despite advances, approximately 8% of the population suffers from asthma, with alarming figures revealing that about 44% of children and 60% of adults experience uncontrolled asthma. The implications of uncontrolled disease include:

  • Increased risk of exacerbations.

  • Consequences of systemic steroid use.

  • Deterioration of quality of life.

Statistics and Projections

Statistics from the CDC reveal the severity of asthma as a health crisis with:

  • Thousands of annual asthma attacks.

  • Tragic fatalities each year attributed to asthma.
    A Canadian study projected that if no changes are made, the number of asthma patients in the U.S. could increase by two million over the next twenty years, along with increased hospital visits and lost work days related to uncontrolled asthma.

Assessing Asthma Control

The assessment of asthma control typically considers two domains:

  1. Risk Domain: Frequency of exacerbations.

  2. Symptom Domain: Daily symptoms affecting life quality.
    In research involving over 4.5 million patients, new definitions for asthma control were established, emphasizing the importance of underlying health practices.

Definition of Control Criteria

Control criteria were set to identify asthma control:

  • Use of three or more SABA (Short-Acting Beta Agonist) canisters per year indicates a lack of control.

  • Two courses of systemic corticosteroids based on criteria established were used to define uncontrolled asthma.

Prevalence of Uncontrolled Asthma

Among 4.5 million patients assessed:

  • About 40,000 patients were on severe asthma therapy.

  • One in two of these patients were classified as uncontrolled.

  • Of the more than 3.8 million patients on mild-moderate therapies, approximately one-third were also deemed uncontrolled, prompting calls for improved referral pathways and management strategies.

Insights from AstraZeneca

AstraZeneca focused on understanding the perspective of clinicians with a listening tour. Initially, many believed no patients were truly uncontrolled, attributing issues to non-compliance. However, as data surfaced, clinicians recognized the necessity for comprehensive control tools that measure both impairment and risk.

Development of Asthma Control Tools

A crucial outcome was the development of the Asthma Impairment and Risk Questionnaire (AIRQ) to simplify asthma control assessment, considering both domains of control. The AIRQ is designed for low literacy usage and can be completed in minutes.

Validation and Educational Component of AIRQ

The AIRQ underwent rigorous validation and was published in "Champion Practice". A pediatric version was also developed, recognizing children have unique asthma control needs compared to adults.

Metrics of AIRQ

The AIRQ consists of:

  • Yes/No Questions: Simple inquiries about daytime symptoms, nighttime awakenings, and rescue medication use.

  • Scoring Mechanism: Answers are scored, with higher scores indicating worse control; 0-1 indicates well-controlled, 2-4 not well controlled, and 5-10 as very poorly controlled.

Comparison of AIRQ with Other Tools

The AIRQ was validated against the established Asthma Control Test (ACT). The sensitivity and specificity of AIRQ exceed those of ACT, indicating its solid predictive power for future exacerbations and potential for clinical application.

Future Assessments and Interventions

The AIRQ also allows clinicians to monitor changes in asthma control after interventions, implementing a three-month look-back period for assessing exacerbation history post-intervention. This systematic way of introducing assessments aids in more timely adjustments of treatment plans.

Consequences of Poor Management

Consequences arise when patients experience exacerbations, often leading to systemic corticosteroid use, associated with a range of long-term health issues, including diabetes and cardiovascular disease. The speaker detailed research highlighting critical thresholds of steroid exposure revealing the significant health risks these patients face.

Environmental and Economic Considerations

The speaker also addressed the environmental impact of asthma management practices, pointing to the significance of reducing carbon footprints linked to inhaled asthma medications. This reflects the dual responsibility of managing individual patient health while considering broader environmental sustainability.

Conclusion

The session concluded with a strong call for better identification, management, and referral paths for uncontrolled asthma patients. It emphasized the need for continuous education, innovative practices, and, ultimately, a holistic approach to handling the complexities involved in asthma healthcare.